Cigarette Smoking Associated With Lung Adenocarcinoma In Situ in a Large Case- Control Study (SFBALCS) Paige M. Bracci, PhD, Jennette Sison, MPH, Helen.

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve Cohort Michèle Beau-Faller, MD,

Su K. Metcalfe, MD, MPH, Michael T

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Approach to the Ground-Glass Nodule

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Yih-Leong Chang, MD, Chen-Tu Wu, MD, Yung-Chie Lee, MD, PhD

Use of Oncogenic Driver Mutations in Staging of Multiple Primary Lung Carcinomas: A Single-Center Experience Ramsey Asmar, MD, Joshua R. Sonett, MD,

Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients Camilla Maria T. Sagerup, MD, Milada.

Electronic Updates for JTO Readers

Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever- Smokers for Lung Cancer Screening Fangyi Gu, ScD, MD, Li C. Cheung,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC? Adrian G.

Telomere Length and Recurrence Risk after Curative Resection in Patients with Early- Stage Non–Small-Cell Lung Cancer: A Prospective Cohort Study Eric.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Yang Zhang, MD, Haiquan Chen, MD, PhD

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Ann G. Schwartz, PhD, Michele L. Cote, PhD, Angela S

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Vamsidhar Velcheti, MD Journal of Thoracic Oncology

ALK Translocation in Non-small Cell Lung Cancer with Adenocarcinoma and Squamous Cell Carcinoma Markers Samuel J. Klempner, MD, David W. Cohen, MD, Daniel.

An Unmet Need in the WHO 2015 Biopsy Classification: Poorly Differentiated NSCCs with Positive Neuroendocrine Markers Jules L. Derks, MD Journal of.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Significance of Smoking as a Postoperative Prognostic Factor in Patients with Non- small Cell Lung Cancer Takeshi Hanagiri, MD, PhD, Kenji Sugio, MD,

Manoj P. Menon, MD, MPH, Keith D. Eaton, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Joan J. Ryoo, MD, MSHS, Jennifer L. Malin, MD, PhD, Diana L

Ethnic Differences in the Management of Lung Cancer in New Zealand

Dan J. Raz, MD, Jason A. Zell, DO, MPH, Anthony N

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

European Lung Cancer Conference (ELCC) 2016 Organisation

S-1 Treatment for Chemorefractory Thymic Carcinoma

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

Epidemiology of Thymoma and Associated Malignancies

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

Cigarette Smoking Associated With Lung Adenocarcinoma In Situ in a Large Case- Control Study (SFBALCS) Paige M. Bracci, PhD, Jennette Sison, MPH, Helen Hansen, BA, Kyle M. Walsh, PhD, Charles P. Quesenberry, PhD, Dan J. Raz, MD, Margaret Wrensch, PhD, John K. Wiencke, PhD Journal of Thoracic Oncology Volume 7, Issue 9, Pages 1352-1360 (September 2012) DOI: 10.1097/JTO.0b013e31825aba47 Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Age- and sex-adjusted OR for all lung cancer, AIS (formerly BAC) non-AIS NSCLC, and lung adenocarcinoma associated with pack-years of smoking (quartiles based on distribution in control cigarette smokers) among whites. Never smokers are the referent group. OR, odds ratio; AIS, adenocarcinoma in situ, BAC, bronchioloalveolar carcinoma, NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2012 7, 1352-1360DOI: (10.1097/JTO.0b013e31825aba47) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Age- and gender-adjusted OR for all lung cancer, AIS (formerly BAC) NSCLC, and lung adenocarcinoma associated with years since quitting smoking [current smokers include those who quit within one year of diagnosis (cases) or interview (controls) and are grouped separately], among whites. Never smokers are the referent group. OR, odds ratio; AIS, adenocarcinoma in situ; BAC, bronchioloalveolar carcinoma; NSCLC, non–small-cell lung cancer. Journal of Thoracic Oncology 2012 7, 1352-1360DOI: (10.1097/JTO.0b013e31825aba47) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions